175 related articles for article (PubMed ID: 9580870)
1. A cost-utility analysis of interferon beta for multiple sclerosis.
Parkin D; McNamee P; Jacoby A; Miller P; Thomas S; Bates D
Health Technol Assess; 1998; 2(4):iii-54. PubMed ID: 9580870
[No Abstract] [Full Text] [Related]
2. Bad decision NICE.
Ellis SJ
Lancet; 2002 Feb; 359(9304):447. PubMed ID: 11844551
[No Abstract] [Full Text] [Related]
3. Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast.
Bryant J; Clegg A; Milne R
BMJ; 2000 May; 320(7247):1474-5; author reply 1475-6. PubMed ID: 10877569
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis.
Nuijten MJ; Hutton J
Value Health; 2002; 5(1):44-54. PubMed ID: 11873383
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
[TBL] [Abstract][Full Text] [Related]
6. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life.
Parkin D; Jacoby A; McNamee P; Miller P; Thomas S; Bates D
J Neurol Neurosurg Psychiatry; 2000 Feb; 68(2):144-9. PubMed ID: 10644777
[TBL] [Abstract][Full Text] [Related]
7. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.
Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C
Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738
[TBL] [Abstract][Full Text] [Related]
8. Interferon beta in multiple sclerosis.
Richards RG
BMJ; 1996 Nov; 313(7066):1159. PubMed ID: 8916730
[No Abstract] [Full Text] [Related]
9. Access denied. While the decision over beta-interferon prescribing hangs in the balance, one thing's for certain--nurses will be left to pick up the pieces.
Thomas S
Nurs Stand; 2000 Jul 19-25; 14(44):20. PubMed ID: 11975272
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis.
Caloyeras JP; Zhang B; Wang C; Eriksson M; Fredrikson S; Beckmann K; Knappertz V; Pohl C; Hartung HP; Shah D; Miller JD; Sandbrink R; Lanius V; Gondek K; Russell MW
Clin Ther; 2012 May; 34(5):1132-44. PubMed ID: 22541587
[TBL] [Abstract][Full Text] [Related]
11. [Interferon-beta in multiple sclerosis--who is going to be treated?].
Aarli JA
Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3114. PubMed ID: 10522472
[No Abstract] [Full Text] [Related]
12. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.
Forbes RB; Lees A; Waugh N; Swingler RJ
BMJ; 1999 Dec; 319(7224):1529-33. PubMed ID: 10591710
[TBL] [Abstract][Full Text] [Related]
13. Shortcomings in pharmacy benefit forecasting--interferon beta products.
Rich SJ; Meyer C
J Manag Care Pharm; 2003; 9(4):373; author reply 374. PubMed ID: 14613461
[No Abstract] [Full Text] [Related]
14. Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.
Kobelt G; Jönsson L; Miltenburger C; Jönsson B
Int J Technol Assess Health Care; 2002; 18(1):127-38. PubMed ID: 11987436
[TBL] [Abstract][Full Text] [Related]
15. Interferon beta, PHARMAC, and political directives: in the best interests of people with multiple sclerosis?
McNaughton H; Kayes N; McPherson K
N Z Med J; 2006 Apr; 119(1232):U1939. PubMed ID: 16633398
[TBL] [Abstract][Full Text] [Related]
16. [A short history of beta-interferon therapy of multiple sclerosis].
Stock G; Horowski R
Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
[TBL] [Abstract][Full Text] [Related]
17. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
Clegg A; Bryant J; Milne R
Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743
[No Abstract] [Full Text] [Related]
18. The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis.
Detournay B
Value Health; 2002; 5(1):1-2. PubMed ID: 11873378
[No Abstract] [Full Text] [Related]
19. Funding of drug treatment of multiple sclerosis should not be delayed.
Paty DW
BMJ; 1997 Nov; 315(7116):1160-1. PubMed ID: 9374903
[No Abstract] [Full Text] [Related]
20. Cost utility of drugs for multiple sclerosis. Analysis goes too far.
Ellis SJ
BMJ; 2000 May; 320(7247):1475-6. PubMed ID: 10877571
[No Abstract] [Full Text] [Related]
[Next] [New Search]
